Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009369/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate complete response plus (+) very good partial
response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination
with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD), in previously untreated
subjects, and in relapsed subjects with multiple myeloma, as defined by the International
Myeloma Working Group (IMWG) criteria.
提供机构：
Vivli
创建时间：
2023-10-17
